The clinical study will enroll approximately 400 patients across 75 sites, utilizing a 2:1 randomization against existing commercial alternatives. To capture a broader range of clinical data, the trial design also includes a single-arm registry for up to 150 patients deemed ineligible for current commercial devices or suboptimal candidates for transcatheter edge-to-edge repair.
In section Releases
Laplace Interventional Secures FDA Approval for TRIUMPH Trial
With FDA Investigational Device Exemption in hand, Minneapolis-based Laplace Interventional is launching the TRIUMPH pivotal trial. The study aims to evaluate the safety and performance of the company's transcatheter tricuspid valve replacement system, targeting a critical treatment gap for patients suffering from severe tricuspid regurgitation.
Leading the investigation are Dr. Charanjit Rihal of the Mayo Clinic, Dr. Kashish Goel of Vanderbilt University Medical Center, and Dr. Brandon Jones of Providence St. Vincent Medical Center. These physicians, whose institutions were the top enrollers in the earlier feasibility study, view the system as a potential leap forward in treating complex anatomies. Company CEO Ramji Iyer stated that the approval marks a transition toward gathering deeper clinical insights for the estimated 1.6 million patients in the U.S. currently living with tricuspid regurgitation.
Comments (0)
No comments yet. Be the first!